On March 10, 2026, Outlook Therapeutics, Inc. held its Annual Meeting, where stockholders elected new directors, ratified KPMG as the accounting firm, and voted on executive compensation; 50.70% of shares were represented. Voting details included Yezan Haddadin receiving 14M+ votes against, while KPMG's selection was ratified by 35M+ votes for.